SLOW K TABLET (EXTENDED-RELEASE)

Country: Canada

Language: English

Source: Health Canada

Active ingredient:

POTASSIUM CHLORIDE

Available from:

NOVARTIS PHARMACEUTICALS CANADA INC

ATC code:

A12BA01

INN (International Name):

POTASSIUM CHLORIDE

Dosage:

600MG

Pharmaceutical form:

TABLET (EXTENDED-RELEASE)

Composition:

POTASSIUM CHLORIDE 600MG

Administration route:

ORAL

Units in package:

100/1000

Prescription type:

Ethical

Therapeutic area:

REPLACEMENT PREPARATIONS

Product summary:

Active ingredient group (AIG) number: 0100273010; AHFS:

Authorization status:

CANCELLED POST MARKET

Authorization date:

2013-02-25

Summary of Product characteristics

_ _
_SLOW-K* _
_Page 1 of 19_
PRODUCT MONOGRAPH
SLOW-K*
Slow-Release Potassium Chloride Tablets
600 mg (8 mEq K
+
)
NOVARTIS Standard
Potassium Supplement
Novartis Pharmaceuticals Canada Inc.
Dorval, Quebec
H9S 1A9
Date of Preparation:
January 28, 1970
Date of Revision:
September 16, 2008
Submission Control No: 118605
SLOW-K* is a registered trademark
_ _
_Appendix E - Product Monograph Template - Standard _
_Page 2 of 19_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................5
ADVERSE
REACTIONS....................................................................................................7
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND
ADMINISTRATION................................................................................8
OVERDOSAGE
..................................................................................................................9
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND
STABILITY..........................................................................................11
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................12
PART II: SCIENTIFIC INFORMATION
...............................................................................13
PHARMACEUTICAL
INFORMATION..........................................................................13
TOXICOLOGY
.....................................................................